Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use SKYRIZI safely and effectively. See full prescribing information for SKYRIZI. SKYRIZI ® (risankizumab-rzaa) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2019
Medication labelWhy this: Advisory · dailymed-prescription
SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy. SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults and pediatric patients 6 years of age and older. SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults. SKYRIZI is indicated for the treatment of moderately to severely active ulcerative colitis in adults.
- generic_name
- risankizumab-rzaa
- brand_name
- isopropyl alcohol
- product_names
- Risankizumab-rzaa, isopropyl alcohol, risankizumab-rzaa
- ndc
- 0074-2042, 0074-2042-02, 0074-2042-71, 0074-1050, 0074-1050-70, 0074-1050-01, 0074-2100, 0074-2100-70, 0074-2100-01, 0074-1070, 0074-1070-01, 0074-1070-02, 0074-1069, 0074-1069-01, 0074-1069-02, 0074-5015, 0074-5015-01, 0074-5015-02, 0074-1065, 0074-1065-01, 0074-1065-02, 0074-1066, 0074-1066-01, 0074-1066-02, 0074-7034, 0074-7034-02, 0074-7032, 0074-7032-01, 0074-7032-90, 0074-7036, 0074-7036-04, 0074-7040, 0074-7040-02, 0074-7042, 0074-7042-04, 0074-8300, 0074-8300-01, 0074-8350, 0074-8350-01, 0074-4059, 0074-4059-01, 0074-4059-71
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en